Alumis (ALMS) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
18 May, 2026Executive summary
The annual meeting will be held virtually on June 30, 2026, to elect three Class II directors and ratify the appointment of PricewaterhouseCoopers LLP as independent auditor for fiscal 2026.
Only stockholders of record as of May 5, 2026, are entitled to vote, with 123,432,072 shares of voting common stock outstanding.
Voting can be done online, by phone, by mail, or during the virtual meeting; votes are counted by Broadridge Financial Solutions.
Stockholder proposals for the 2027 annual meeting must be submitted by January 18, 2027, for inclusion in proxy materials.
Voting matters and shareholder proposals
Proposal 1: Election of three Class II directors (James B. Tananbaum, Lynn Tetrault, Zhengbin Yao) to serve until 2029.
Proposal 2: Ratification of PricewaterhouseCoopers LLP as independent auditor for fiscal year ending December 31, 2026.
Board recommends voting “FOR” all director nominees and auditor ratification.
Shareholders may submit proposals for the 2027 meeting by January 18, 2027, or nominate directors between March 2 and April 1, 2027.
Board of directors and corporate governance
Board consists of eight members divided into three classes, with staggered three-year terms.
Majority of directors are independent under Nasdaq rules; only the CEO is not independent.
Board leadership combines CEO and Chairman roles, with a lead independent director appointed in June 2025.
Four standing committees: Audit, Compensation, Nominating and Corporate Governance, and Science and Technology.
Board and committees conduct annual self-evaluations; directors are assessed for overboarding.
Code of Business Conduct and Ethics and an insider trading policy are in place.
Latest events from Alumis
- Election of three directors and auditor ratification to be decided at June 2026 virtual meeting.ALMS
Proxy filing18 May 2026 - Envudeucitinib delivers leading efficacy in psoriasis, with broad TYK2 franchise potential.ALMS
Corporate presentation14 May 2026 - Envudeucitinib's Phase 3 success drives NDA plans as $569.5M cash supports operations into 2027.ALMS
Q1 202614 May 2026 - Envudeucitinib achieved rapid, sustained skin clearance and symptom relief with strong safety in Phase 3 trials.ALMS
Study update30 Mar 2026 - Envudeucitinib achieved top Phase 3 results in psoriasis, driving a high-value, multi-indication pipeline.ALMS
Corporate presentation19 Mar 2026 - Envudeucitinib's Phase 3 success and robust financing position operations through late 2027.ALMS
Q4 202519 Mar 2026 - Envudeucitinib delivers leading efficacy in psoriasis, with broad TYK2 franchise expansion ahead.ALMS
Leerink Global Healthcare Conference 20269 Mar 2026 - Strong Phase 3 psoriasis data and NDA planned; SLE pivotal trial readout expected in Q3.ALMS
Oppenheimer 36th Annual Healthcare Life Sciences Conference26 Feb 2026 - Strong phase III psoriasis results and robust pipeline expansion, with NDA filing expected this year.ALMS
Guggenheim Securities Emerging Outlook: Biotech Summit 202612 Feb 2026